Picture of Alpha Cognition logo

ACOG Alpha Cognition Share Price

0.000.00%
ca flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-9.15%
3m-12.84%
6m-33.22%
1yr-28.95%
Volume Change (%)
10d/3m-84.53%
Price vs... (%)
52w High-72.29%
50d MA+9.11%
200d MA-25.94%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-137.59%
Return on Equity-367.24%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Alpha Cognition EPS forecast chart

Profile Summary

Alpha Cognition Inc. is a Canada-based biopharmaceutical company principally engaged in developing treatments for neurodegenerative diseases such as Alzheimer’s Disease and Amyotrophic Lateral Sclerosis (ALS). The Company’s therapeutic pipeline includes ALPHA-1062 and ALPHA-0602. The Company’s ALPHA-1062 development program is primarily focused on clinical and regulatory development, chemistry, manufacturing and control development, and commercial readiness. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein, and is in preclinical development for the treatment of amyotrophic lateral sclerosis. It has three development programs: ALPHA-1062 in combination with memantine for the treatment of moderate-to-severe Alzheimer’s; ALPHA-1062 nasal formulation for the treatment of mild traumatic brain injury, and ALPHA-0602, for the treatment of amyotrophic lateral sclerosis. ALPHA-1062 is also being researched as a treatment for mild-traumatic brain injury.

Directors

    Last Annual
    December 31st, 2021
    Last Interim
    March 31st, 2022
    Incorporated
    November 15th, 2017
    Public Since
    September 19th, 2018
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    ca flag iconTSX Venture Exchange
    Shares in Issue
    61,023,450
    Blurred out image of a map
    Address
    439 Helmcken Street, Vancouver, V6B 2E6
    Web
    Phone
    Auditors
    Manning Elliott LLP

    ACOG Share Price Performance

    Upcoming Events for ACOG

    Similar to ACOG

    Picture of Advanced Proteome Therapeutics logo

    Advanced Proteome Therapeutics

    ca flag iconTSX Venture Exchange

    Picture of Arch Biopartners logo

    Arch Biopartners

    ca flag iconTSX Venture Exchange

    Picture of biOasis Technologies logo

    biOasis Technologies

    ca flag iconTSX Venture Exchange

    Picture of Ceapro logo

    Ceapro

    ca flag iconTSX Venture Exchange

    Picture of Claritas Pharmaceuticals logo

    Claritas Pharmaceuticals

    ca flag iconTSX Venture Exchange

    FAQ

    Or unlock with your email

    Or unlock with your email